Advanced search
Start date
Betweenand

Characterization of Leishmania (v.) braziliensis clinical isolates susceptibility to miltefosine in vitro and in vivo

Grant number: 15/05130-5
Support type:Scholarships in Brazil - Master
Effective date (Start): July 01, 2015
Effective date (End): February 28, 2017
Field of knowledge:Biological Sciences - Parasitology - Protozoology of Parasites
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal Investigator:Silvia Reni Bortolin Uliana
Grantee:Caroline Ricce Espada
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Leishmaniasis is a disease caused by parasites of Leishmania genus. In Brazil, the cutaneous form of the disease is mainly caused by Leishmania (V.) braziliensis, with an annual incidence of approximately 26,000 cases in 2012. The drugs available for the treatment of leishmaniasis have limitations as high toxicity and the need of parenteral administration, which can result in interruption of treatment and consequent selection of resistant parasites. Miltefosine is an oral drug, already available for the treatment of leishmaniasis in some countries, but is not used in Brazil yet. It is known that susceptibility to miltefosine varies among species and among isolates of the same Leishmania species and yet there are not available data showing the susceptibility of L. (V.) braziliensis Brazilian isolates to miltefosine. Thus, this project aims to evaluate the susceptibility of clinical isolates of patients from two different geographical regions of Brazil to miltefosine and elucidate the molecular basis of the differences in susceptibility to miltefosine in these isolates. Thus, inhibitory concentrations of miltefosine in vitro, using intracellular amastigotes of 9 clinical isolates, will be determined. Based on these data, the two isolates with higher and lower susceptibility to the drug isolates will be selected for in vivo studies. The two selected isolates, will also be characterized by the transport of phospholipids in the plasma membrane and the nucleotide sequences of the genes encoding the miltefosine transporter, in order to verify if polymorphisms in these genes can be associated with susceptibility variation found in these isolates. (AU)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
TRINCONI, CRISTIANA T.; REIMAO, JULIANA Q.; BONANO, I, VIVIAN; ESPADA, CAROLINE R.; MIGUEL, DANILO C.; YOKOYAMA-YASUNAKA, JENICER K. U.; ULIANA, SILVIA R. B. Topical tamoxifen in the therapy of cutaneous leishmaniasis. Parasitology, v. 145, n. 4, SI, p. 490-496, APR 2018. Web of Science Citations: 10.
ESPADA, CAROLINE R.; RIBEIRO-DIAS, FATIMA; DORTA, MIRIAM L.; DE ARAUJO PEREIRA, LEDICE INACIA; DE CARVALHO, EDGAR M.; MACHADO, PAULO R.; SCHRIEFER, ALBERT; YOKOYAMA-YASUNAKA, JENICER K. U.; COELHO, ADRIANO C.; ULIANA, SILVIA R. B. Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis. American Journal of Tropical Medicine and Hygiene, v. 96, n. 3, p. 656-659, 2017. Web of Science Citations: 2.
COELHO, ADRIANO C.; OLIVEIRA, JORDANA C.; ESPADA, CAROLINE R.; REIMAO, JULIANA Q.; TRINCONI, CRISTIANA T.; ULIANA, SILVIA R. B. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome. PLoS Neglected Tropical Diseases, v. 10, n. 5 MAY 2016. Web of Science Citations: 4.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.